Biogen Inc. (Nasdaq: BIIB) announced upcoming data presentations and programming at the Clinical Trials on Alzheimer’s Disease (CTAD) annual conference, taking place October 29 - November 1, in Madrid ...

Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research ...

The UK’s National Institute of Health and Care Excellence (NICE) said the drug provided only a small benefit to patients.

Diagnosed with mild cognitive impairment (MCI) in 2018, Mr Almond, from Esher, took part in two 18-month trials for donanemab ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) founder Lars Lannfelt will be presented with the Lifetime Achievement Award in ...

Health spending watchdog said costs could not justify benefits after treatment slowed cognitive decline by around four to ...

The Alzheimer's Society Cymru has responded to the approval of a new Alzheimer's treatment. The Medicines and Healthcare products Regulatory Agency (MHRA) announced on Wednesday, October 23, that it ...

A wife whose husband will not be eligible for new Alzheimer’s drugs has implored health leaders to ensure that others like ...

A couple from Hull have called on the government to fund new Alzheimer's drugs, even though they say it will come "too late" ...

Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...

The UK’s healthcare spending watchdog has rejected Eli Lilly’s (LLY) Alzheimer’s drug as being too expensive despite being ...

A second groundbreaking drug (donanemab) for Alzheimer's disease has been rejected for widespread use by the NHS in England ...